{"id":118792,"date":"2026-06-16T10:51:17","date_gmt":"2026-06-16T05:21:17","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=118792"},"modified":"2026-06-16T10:51:18","modified_gmt":"2026-06-16T05:21:18","slug":"kopran-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/","title":{"rendered":"Kopran Share Price Target 2026 Analyst Forecast Bull and Bear Case"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>The Kopran share price target 2026 is Rs 220, implying approximately 20 percent upside from the current market price of Rs 183.38 (NSE: KOPRAN-BE). With Q4 FY26 results released in 2026 and Pharmaceutical APIs and Formulations tailwinds in focus, the Rs 220 price objective is supported by the FY27 earnings recovery thesis.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/user\/stocks\/kopran\/kopran-ltd-share-price-today\">Kopran<\/a> (NSE: KOPRAN-BE) is a Pharmaceutical APIs and Formulations company trading at Rs 183.38 with a market capitalisation of Rs 918 crore. Analysts have set the <strong>Kopran share price target<\/strong> at Rs 220 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast for Kopran including sector tailwinds, key risks, and the bull and bear scenarios.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Kopran_Share_Price_Target_2026_Key_Takeaways\" title=\"Kopran Share Price Target 2026: Key Takeaways\">Kopran Share Price Target 2026: Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Kopran_Company_Overview\" title=\"Kopran Company Overview\">Kopran Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Why_Is_the_Kopran_Share_Price_Target_Set_at_Rs_220_for_2026\" title=\"Why Is the Kopran Share Price Target Set at Rs 220 for 2026\">Why Is the Kopran Share Price Target Set at Rs 220 for 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#FY27_Earnings_Recovery_and_Revenue_Acceleration\" title=\"FY27 Earnings Recovery and Revenue Acceleration\">FY27 Earnings Recovery and Revenue Acceleration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Structural_Sector_Tailwinds_in_Pharmaceutical_APIs_and_Formulations\" title=\"Structural Sector Tailwinds in Pharmaceutical APIs and Formulations\">Structural Sector Tailwinds in Pharmaceutical APIs and Formulations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\" title=\"RBI Rate Cut Cycle and Lower Cost of Capital\">RBI Rate Cut Cycle and Lower Cost of Capital<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Union_Budget_2026-27_Capex_Push_and_Policy_Support\" title=\"Union Budget 2026-27 Capex Push and Policy Support\">Union Budget 2026-27 Capex Push and Policy Support<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#FII_Flow_Normalisation_After_the_2026_Tariff_Shock\" title=\"FII Flow Normalisation After the 2026 Tariff Shock\">FII Flow Normalisation After the 2026 Tariff Shock<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Kopran_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\" title=\"Kopran Share Price Targets: Short Term, 12 Month, and Long Term\">Kopran Share Price Targets: Short Term, 12 Month, and Long Term<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Short_Term_Kopran_Share_Price_Target\" title=\"Short Term Kopran Share Price Target\">Short Term Kopran Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#12-Month_Kopran_Share_Price_Target_2026\" title=\"12-Month Kopran Share Price Target 2026\">12-Month Kopran Share Price Target 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Long_Term_Kopran_Share_Price_Target_FY27_to_FY28\" title=\"Long Term Kopran Share Price Target: FY27 to FY28\">Long Term Kopran Share Price Target: FY27 to FY28<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Bull_Case_and_Bear_Case_Scenarios_for_Kopran_in_2026\" title=\"Bull Case and Bear Case Scenarios for Kopran in 2026\">Bull Case and Bear Case Scenarios for Kopran in 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Bull_Case_Kopran_Share_Price_Target_Rs_265\" title=\"Bull Case Kopran Share Price Target: Rs 265\">Bull Case Kopran Share Price Target: Rs 265<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Bear_Case_Kopran_Share_Price_Target_Rs_145\" title=\"Bear Case Kopran Share Price Target: Rs 145\">Bear Case Kopran Share Price Target: Rs 145<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Key_Risks_That_Could_Derail_the_Kopran_2026_Price_Objective\" title=\"Key Risks That Could Derail the Kopran 2026 Price Objective\">Key Risks That Could Derail the Kopran 2026 Price Objective<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Global_Macro_and_US_Tariff_Headwinds\" title=\"Global Macro and US Tariff Headwinds\">Global Macro and US Tariff Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#FY27_Earnings_Miss_and_Guidance_Risk\" title=\"FY27 Earnings Miss and Guidance Risk\">FY27 Earnings Miss and Guidance Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Competitive_Intensity_Among_Pharmaceutical_APIs_and_Formulations_Peers\" title=\"Competitive Intensity Among Pharmaceutical APIs and Formulations Peers\">Competitive Intensity Among Pharmaceutical APIs and Formulations Peers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Liquidity_Risk_and_FII_Selling_Pressure\" title=\"Liquidity Risk and FII Selling Pressure\">Liquidity Risk and FII Selling Pressure<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#How_to_Invest_in_Kopran_A_Step-by-Step_Approach\" title=\"How to Invest in Kopran: A Step-by-Step Approach\">How to Invest in Kopran: A Step-by-Step Approach<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#FAQs_on_Kopran_Share_Price_Target_2026\" title=\"FAQs on Kopran Share Price Target 2026\">FAQs on Kopran Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#What_is_the_Kopran_share_price_target_for_2026\" title=\"What is the Kopran share price target for 2026?\">What is the Kopran share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#What_was_the_Kopran_share_price_target_for_2025\" title=\"What was the Kopran share price target for 2025?\">What was the Kopran share price target for 2025?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#Is_Kopran_a_good_investment_at_Rs_18338\" title=\"Is Kopran a good investment at Rs 183.38?\">Is Kopran a good investment at Rs 183.38?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#What_are_the_key_risks_to_the_Kopran_share_price_target_2026\" title=\"What are the key risks to the Kopran share price target 2026?\">What are the key risks to the Kopran share price target 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#What_is_the_52_week_high_and_low_of_Kopran\" title=\"What is the 52 week high and low of Kopran?\">What is the 52 week high and low of Kopran?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#What_are_the_main_growth_catalysts_for_Kopran_in_2026\" title=\"What are the main growth catalysts for Kopran in 2026?\">What are the main growth catalysts for Kopran in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#How_does_Kopran_compare_to_its_peers\" title=\"How does Kopran compare to its peers?\">How does Kopran compare to its peers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/kopran-share-price-target-2026\/#What_is_the_Kopran_share_price_target_for_2027\" title=\"What is the Kopran share price target for 2027?\">What is the Kopran share price target for 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Kopran_Share_Price_Target_2026_Key_Takeaways\"><\/span><strong>Kopran Share Price Target 2026: Key Takeaways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Kopran share price target 2026:<\/strong> Rs 220 (20% upside from CMP Rs 183.38)<\/li>\n<li><strong>Bull case:<\/strong> Rs 265 | <strong>Bear case:<\/strong> Rs 145<\/li>\n<li><strong>Ticker:<\/strong> KOPRAN-BE | <strong>Sector:<\/strong> Pharmaceutical APIs and Formulations | <strong>MCap:<\/strong> Rs 918 crore<\/li>\n<li><strong>52W range:<\/strong> Rs 128 to Rs 310 | <strong>PE:<\/strong> 15x<\/li>\n<li><strong>Key catalyst:<\/strong> Q4 FY26 results and FY27 earnings recovery confirmation in 2026<\/li>\n<li><strong>Key risk:<\/strong> FY27 earnings miss or sustained FII outflows from Indian equities<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Kopran_Company_Overview\"><\/span><strong>Kopran Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Kopran (NSE: KOPRAN-BE) is a Mumbai-based pharmaceutical company manufacturing APIs, fine chemicals, and formulations for domestic and regulated export markets, with a focus on macrolide antibiotics and specialty APIs. At CMP Rs 183.38 against a 52 week range of Rs 128 to Rs 310, the stock is trading at a meaningful discount to its 52 week high. The trailing PE is 15x and the Rs 220 analyst target implies approximately 20 percent upside from current levels. Compared to peers in pharma APIs like Divi&#8217;s Laboratories and Laurus Labs, Kopran is positioned as a potential re-rating candidate on FY27 earnings delivery.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>KOPRAN-BE<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceutical APIs and Formulations<\/td>\n<\/tr>\n<tr>\n<td>CMP (2026)<\/td>\n<td>Rs 183.38<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 310<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 128<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 918 crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing PE<\/td>\n<td>15x<\/td>\n<\/tr>\n<tr>\n<td>12-Month Analyst Target<\/td>\n<td>Rs 220<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 265<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 145<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #E8EAFF; border-radius: 14px; padding: 28px 32px 24px 32px; margin: 24px 0; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,sans-serif; cursor: pointer; max-width: 100%; box-sizing: border-box;\">\n<p style=\"font-size: 20px; font-weight: bold; color: #0a0a23; margin: 0 0 12px 0; line-height: 1.3;\">3 Stocks Building Serious Momentum Right Now<\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">When <strong style=\"color: #0a0a23;\">Univest analysts<\/strong> identify high-conviction stock opportunities, <em>investors pay attention.<\/em><\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">Our research team has shortlisted the <strong style=\"color: #0a0a23;\">Top Stocks to Buy<\/strong> based on market momentum, sector trends &amp; growth potential for 2026.<\/p>\n<ul style=\"margin: 0 0 16px 20px; padding: 0; color: #3a3a5c; font-size: 15px; line-height: 1.8;\">\n<li>Discover stocks investors are actively accumulating<\/li>\n<li>High-conviction opportunities backed by research<\/li>\n<li>Designed for the next phase of market growth<\/li>\n<\/ul>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 20px 0;\">Unlock the latest <a style=\"color: #3b7fff; font-weight: bold; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/payment?planType=ALL_PRO%20PLANS\" target=\"_blank\" rel=\"noopener\">Top Stock Picks<\/a> now on Univest<\/p>\n<p><a style=\"display: inline-block; background: #3B7FFF; color: #fff; font-size: 15px; font-weight: 600; padding: 13px 28px; border-radius: 50px; letter-spacing: 0.2px; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/payment?planType=ALL_PRO%20PLANS\" target=\"_blank\" rel=\"noopener\">See the Stocks \u2192<\/a><\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_the_Kopran_Share_Price_Target_Set_at_Rs_220_for_2026\"><\/span><strong>Why Is the Kopran Share Price Target Set at Rs 220 for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Recovery_and_Revenue_Acceleration\"><\/span><strong>FY27 Earnings Recovery and Revenue Acceleration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>Kopran share price target<\/strong> of Rs 220 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for a re-rating. Until FY27 PAT delivery is confirmed, the Rs 220 price objective represents a base case with execution risk attached.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Structural_Sector_Tailwinds_in_Pharmaceutical_APIs_and_Formulations\"><\/span><strong>Structural Sector Tailwinds in Pharmaceutical APIs and Formulations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Pharmaceutical APIs and Formulations sector is expanding on the back of India&#8217;s domestic demand growth, PLI scheme support, and rising corporate investment. Kopran&#8217;s position among peers in pharma APIs like Divi&#8217;s Laboratories and Laurus Labs creates a structural growth runway. Sustained sector outperformance is one of the key conditions for the Rs 265 bull case to materialise, making sector monitoring essential for investors tracking this stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\"><\/span><strong>RBI Rate Cut Cycle and Lower Cost of Capital<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s RBI rate cut cycle in 2026 is reducing borrowing costs across sectors and stimulating end market demand. For Kopran, lower interest costs improve the EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 220 analyst consensus. This rate environment is a tailwind across the Pharmaceutical APIs and Formulations space.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Union_Budget_2026-27_Capex_Push_and_Policy_Support\"><\/span><strong>Union Budget 2026-27 Capex Push and Policy Support<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Budget 2026-27&#8217;s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a favourable policy backdrop for Kopran&#8217;s Pharmaceutical APIs and Formulations operations. Policy support increases the probability of Kopran achieving its FY27 earnings targets, which in turn supports the Rs 220 price objective set by analysts for 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FII_Flow_Normalisation_After_the_2026_Tariff_Shock\"><\/span><strong>FII Flow Normalisation After the 2026 Tariff Shock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 15x PE, Kopran is positioned as a beneficiary of institutional reallocation into mid-cap and small-cap Indian stocks. Sustained FII inflow is a necessary condition for re-rating the stock toward the Rs 265 bull case scenario.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Kopran_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\"><\/span><strong>Kopran Share Price Targets: Short Term, 12 Month, and Long Term<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Kopran_Share_Price_Target\"><\/span><strong>Short Term Kopran Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Near-term support for Kopran is anchored near the 52 week low of Rs 128. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors eyeing a near-term entry can use the 52 week low as a key reference while awaiting the FY27 earnings confirmation that would strengthen the case for the full price objective of Rs 220.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12-Month_Kopran_Share_Price_Target_2026\"><\/span><strong>12-Month Kopran Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month <strong>Kopran share price target 2026<\/strong> is Rs 220, implying approximately 20 percent upside from CMP Rs 183.38. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Investors can track live price movement on NSE under the ticker KOPRAN-BE to assess progress toward this target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Long_Term_Kopran_Share_Price_Target_FY27_to_FY28\"><\/span><strong>Long Term Kopran Share Price Target: FY27 to FY28<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>long term Kopran share price target<\/strong> for the FY27 to FY28 period is Rs 265 in the bull case. Full earnings delivery, re-rating toward higher peer multiples among peers in pharma APIs like Divi&#8217;s Laboratories and Laurus Labs, and sustained institutional buying are the three conditions that need to align for the stock to reach the Rs 265 level over a 2 to 3 year horizon.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Bear_Case_Scenarios_for_Kopran_in_2026\"><\/span><strong>Bull Case and Bear Case Scenarios for Kopran in 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Kopran_Share_Price_Target_Rs_265\"><\/span><strong>Bull Case Kopran Share Price Target: Rs 265<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bull case Kopran share price target<\/strong> of Rs 265 materialises when FY27 earnings beat analyst estimates, Pharmaceutical APIs and Formulations tailwinds accelerate beyond consensus, and FII flows return strongly to Indian equities. Under this scenario, Kopran re-rates toward higher peer multiples, making Rs 265 achievable within FY28. The current gap between CMP Rs 183.38 and Rs 265 represents approximately 45 percent potential upside.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bear_Case_Kopran_Share_Price_Target_Rs_145\"><\/span><strong>Bear Case Kopran Share Price Target: Rs 145<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bear case Kopran share price target<\/strong> of Rs 145 materialises if FY27 earnings disappoint, management guides below expectations, or sustained FII outflows depress the broader mid-cap market. Under this scenario, the stock risks testing the 52 week low support near Rs 128, and investors should reassess the investment thesis before adding more capital.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target<\/th>\n<th>Key Conditions<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 265<\/td>\n<td>FY27 earnings beat, sector re-rating, FII inflows<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Analyst Target)<\/td>\n<td>Rs 220<\/td>\n<td>In-line FY27 delivery, partial FII recovery<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 145<\/td>\n<td>FY27 miss, guidance cut, FII outflows persist<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_That_Could_Derail_the_Kopran_2026_Price_Objective\"><\/span><strong>Key Risks That Could Derail the Kopran 2026 Price Objective<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Global_Macro_and_US_Tariff_Headwinds\"><\/span><strong>Global Macro and US Tariff Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The prolonged tariff tension triggered by the US reciprocal tariff announcement in 2026 has reduced FII risk appetite for Indian equities. A global demand slowdown or escalation in trade tensions remains the most prominent macro risk to the <strong>Kopran share price target<\/strong> of Rs 220 and could push the stock toward the bear case of Rs 145.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Miss_and_Guidance_Risk\"><\/span><strong>FY27 Earnings Miss and Guidance Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Any FY27 earnings miss or downward guidance revision by Kopran&#8217;s management would compress valuation multiples. This is the most direct company-specific risk to the Rs 220 analyst price objective. Investors should monitor quarterly results and management commentary closely, especially any signals about demand environment, pricing power, or margin compression in the Pharmaceutical APIs and Formulations segment.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Competitive_Intensity_Among_Pharmaceutical_APIs_and_Formulations_Peers\"><\/span><strong>Competitive Intensity Among Pharmaceutical APIs and Formulations Peers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Intensifying competition from peers in pharma APIs like Divi&#8217;s Laboratories and Laurus Labs could compress Kopran&#8217;s market share and pricing power over the medium term. This structural risk must be weighed when assessing how defensible the earnings trajectory that underpins the Rs 220 analyst target truly is, particularly as new entrants and imports from China disrupt established market structures.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_Risk_and_FII_Selling_Pressure\"><\/span><strong>Liquidity Risk and FII Selling Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level operational improvement. For smaller market cap stocks, liquidity constraints can amplify drawdowns significantly. Investors should size positions carefully and maintain stop losses to protect capital if the broader market de-rating continues through FY27.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Kopran_A_Step-by-Step_Approach\"><\/span><strong>How to Invest in Kopran: A Step-by-Step Approach<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data<\/strong><\/a><\/p>\n<p>Before considering any investment based on the <strong>Kopran share price target<\/strong> of Rs 220, review the company&#8217;s Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, operating margin trends, debt levels, and management commentary on Pharmaceutical APIs and Formulations sector demand and competition.<\/p>\n<p>Open a Demat and trading account with a SEBI registered stockbroker to trade Kopran (NSE: KOPRAN-BE) with regulatory protection. Complete KYC, and before executing any order, study the competitive landscape among peers in pharma APIs like Divi&#8217;s Laboratories and Laurus Labs to assess whether Kopran&#8217;s competitive position justifies the Rs 220 valuation.<\/p>\n<p>Plan your entry using technical and fundamental triggers. The 52 week low of Rs 128 acts as a key support reference. A confirmed FY27 earnings uptick combined with positive guidance would validate the entry case. Always set a pre-defined stop loss below the 52 week low to limit downside.<\/p>\n<p>Maintain position sizing discipline. Restrict any single stock to 3 to 5 percent of your total equity portfolio. This is especially important in the Pharmaceutical APIs and Formulations space where sectoral cycles, regulatory changes, and commodity price swings can amplify volatility beyond initial expectations.<\/p>\n<p>Always consult a SEBI registered financial advisor before making investment decisions based on any analyst price target or market commentary. SEBI Registration No. INH000013776.<\/p>\n<p><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Kopran&#8217;s live share price and receive daily stock recommendations from SEBI registered analysts.<\/em><\/p>\n<div style=\"background: #C0392B; padding: 20px 24px; border-radius: 4px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 15px; font-weight: bold; margin: 0; line-height: 1.7;\"><strong>Disclaimer Note:<\/strong> The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Kopran_Share_Price_Target_2026\"><\/span><strong>FAQs on Kopran Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Kopran_share_price_target_for_2026\"><\/span><strong>What is the Kopran share price target for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Kopran share price target 2026 is Rs 220, implying approximately 20 percent upside from CMP Rs 183.38. The bull case estimate is Rs 265 and the bear case is Rs 145.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_Kopran_share_price_target_for_2025\"><\/span><strong>What was the Kopran share price target for 2025?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 2025 price target for Kopran was based on FY26 earnings projections. The current 2026 analyst consensus stands at Rs 220, reflecting FY27 growth potential from CMP Rs 183.38.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Kopran_a_good_investment_at_Rs_18338\"><\/span><strong>Is Kopran a good investment at Rs 183.38?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> At Rs 183.38, Kopran offers potential upside toward Rs 220 if FY27 earnings recover as projected. Whether the stock is a good buy depends on individual risk appetite, investment horizon, and portfolio goals. Consult a SEBI registered financial advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_Kopran_share_price_target_2026\"><\/span><strong>What are the key risks to the Kopran share price target 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks to the Kopran share price target of Rs 220 include FY27 earnings miss, global tariff headwinds, sustained FII outflows, and competitive pressure in the Pharmaceutical APIs and Formulations sector. Monitoring quarterly results closely is essential.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52_week_high_and_low_of_Kopran\"><\/span><strong>What is the 52 week high and low of Kopran?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 52 week high of Kopran is Rs 310 and the 52 week low is Rs 128. At CMP Rs 183.38, the stock is trading below its 52 week high and offers upside potential toward the Rs 220 analyst price objective.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_growth_catalysts_for_Kopran_in_2026\"><\/span><strong>What are the main growth catalysts for Kopran in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Primary growth catalysts for Kopran in 2026 include FY27 PAT recovery, Pharmaceutical APIs and Formulations sector tailwinds, RBI rate cuts reducing cost of capital, Union Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Kopran_compare_to_its_peers\"><\/span><strong>How does Kopran compare to its peers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Kopran operates in Pharmaceutical APIs and Formulations alongside peers in pharma APIs like Divi&#8217;s Laboratories and Laurus Labs. At CMP Rs 183.38 with MCap Rs 918 crore, the company is positioned as a potential re-rating candidate toward the Kopran share price target of Rs 220 on FY27 earnings delivery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Kopran_share_price_target_for_2027\"><\/span><strong>What is the Kopran share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The long-term Kopran share price target for FY27 to FY28 is Rs 265 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows. Consult a SEBI registered financial advisor for personalised guidance.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Kopran share price target 2026 is Rs 220, ~20% upside from CMP Rs 183.38. Bull Rs 265, bear Rs 145. 2026.<\/p>\n","protected":false},"author":35,"featured_media":119090,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-118792","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1781587281:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["83"],"rank_math_title":["Kopran Share Price Target 2026: Rs 220 Analyst Forecast"],"rank_math_description":["The Kopran share price target 2026 is Rs 220, ~20% upside from CMP Rs 183.38. Bull Rs 265, bear Rs 145. 2026."],"rank_math_focus_keyword":["Kopran share price target"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["119090"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["18220"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Kopran-Share-Price-Target-2026-Analyst-Forecast-Bull-and-Bear.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/118792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=118792"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/118792\/revisions"}],"predecessor-version":[{"id":119091,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/118792\/revisions\/119091"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/119090"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=118792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=118792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=118792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}